Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $129.00 Price Target at Robert W. Baird

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target hoisted by research analysts at Robert W. Baird from $112.00 to $129.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 17.19% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Evercore set a $126.00 target price on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Royal Bank Of Canada dropped their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. HC Wainwright raised their price target on shares of Mirum Pharmaceuticals from $150.00 to $175.00 and gave the company a “buy” rating in a research report on Monday. Morgan Stanley increased their target price on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Leerink Partners decreased their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $126.67.

Mirum Pharmaceuticals Trading Up 4.0%

Shares of NASDAQ MIRM opened at $110.08 on Thursday. Mirum Pharmaceuticals has a 1 year low of $40.00 and a 1 year high of $110.49. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The firm has a 50-day moving average of $93.88 and a 200 day moving average of $85.86. The stock has a market cap of $6.71 billion, a P/E ratio of -229.33 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($13.06). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. During the same period in the prior year, the business posted ($0.30) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, sell-side analysts expect that Mirum Pharmaceuticals will post -1.81 EPS for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 7,287 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the chief financial officer directly owned 49,788 shares in the company, valued at $4,579,500.24. The trade was a 12.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at $17,872,541.82. This trade represents a 17.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 76,806 shares of company stock valued at $7,064,616 in the last 90 days. Insiders own 14.36% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after buying an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mirum Pharmaceuticals by 7.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after acquiring an additional 1,720 shares during the period. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals during the 1st quarter worth approximately $217,000. Finally, Empowered Funds LLC raised its stake in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after acquiring an additional 5,120 shares during the period.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Clinical milestone — Mirum announced the primary endpoint was met in the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC), a meaningful catalyst that expands the company’s late‑stage pipeline value and underpins renewed investor interest. Read More.
• Positive Sentiment: Revenue beat and guidance lift — Q1 revenue came in at $159.9M (up 43% YoY) versus analyst estimates near $148.2M, and management raised FY2026 revenue guidance to $660–$680M (above consensus of ~$644M), supporting upside to near‑term sales expectations. Read More.
• Positive Sentiment: Investor/analyst attention and M&A chatter — media coverage highlights a >$1B addressable opportunity and new analyst target moves and buyout speculation, which can attract retail and institutional buying. Read More.
• Neutral Sentiment: Record of management commentary — the earnings conference call transcript is available for detail on drivers, commercial uptake and cadence of pipeline programs; investors will parse commentary for sustainability of revenue and timing of launch/label expansion. Read More.
• Negative Sentiment: EPS confusion and reported miss — some reported EPS figures looked worse than expected (one feed showed a large negative figure driven by non‑recurring items), creating headline risk; the company still shows negative net margin and ROE, and that may temper enthusiasm until accounting noise is reconciled. Read More.
• Negative Sentiment: Analyst downward revisions to EPS models — HC Wainwright trimmed Q3/Q4 and FY2026 EPS estimates (while keeping a buy rating and $175 PT), suggesting near‑term profitability will be weaker than previously modeled. Read More.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.